AU2019319745B2 - 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases - Google Patents
2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases Download PDFInfo
- Publication number
- AU2019319745B2 AU2019319745B2 AU2019319745A AU2019319745A AU2019319745B2 AU 2019319745 B2 AU2019319745 B2 AU 2019319745B2 AU 2019319745 A AU2019319745 A AU 2019319745A AU 2019319745 A AU2019319745 A AU 2019319745A AU 2019319745 B2 AU2019319745 B2 AU 2019319745B2
- Authority
- AU
- Australia
- Prior art keywords
- alkyl
- compound
- chosen
- alkoxy
- perfluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
- C07F9/65068—Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862714962P | 2018-08-06 | 2018-08-06 | |
| US62/714,962 | 2018-08-06 | ||
| PCT/US2019/045229 WO2020033359A1 (en) | 2018-08-06 | 2019-08-06 | 2-arylbenzimidazoles as ppargc1a activators for treating neurodegenerative diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2019319745A1 AU2019319745A1 (en) | 2021-03-25 |
| AU2019319745B2 true AU2019319745B2 (en) | 2025-06-26 |
Family
ID=69413327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019319745A Active AU2019319745B2 (en) | 2018-08-06 | 2019-08-06 | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US12195432B2 (https=) |
| EP (1) | EP3833344A4 (https=) |
| JP (2) | JP7422737B2 (https=) |
| KR (1) | KR20210068399A (https=) |
| CN (2) | CN112805000A (https=) |
| AU (1) | AU2019319745B2 (https=) |
| BR (1) | BR112021002165A2 (https=) |
| CA (1) | CA3108773A1 (https=) |
| IL (3) | IL307972A (https=) |
| MX (2) | MX2021001456A (https=) |
| SG (1) | SG11202101285YA (https=) |
| TW (1) | TWI904076B (https=) |
| WO (1) | WO2020033359A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210068399A (ko) | 2018-08-06 | 2021-06-09 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 주니어 유니버시티 | 신경퇴행성 질병의 치료를 위한 피피에이알지씨1알파 활성제로서 2-아릴벤즈이미다졸 |
| WO2021181364A1 (en) * | 2020-03-13 | 2021-09-16 | Biorchestra Co., Ltd. | Diagnostic methods using pgc-1α expression |
| CN112933232A (zh) * | 2021-02-02 | 2021-06-11 | 袁玉佳 | PGC-1α激活TFEB介导的自噬在制备治疗急性肾损伤的药物中的应用 |
| EP4426295A1 (en) * | 2021-11-02 | 2024-09-11 | Tranquis Therapeutics, Inc. | Selection and treatment of subjects having a circulating myeloid cell inflammatory phenotype |
| US20250262189A1 (en) * | 2022-04-22 | 2025-08-21 | Rdiscovery, LLC | Treatment of diseases associated with reductive stress |
| KR20250144994A (ko) * | 2022-11-18 | 2025-10-13 | 사토시 고조 | Zln-005 및 관련 화합물의 용도 |
| WO2024118936A1 (en) * | 2022-12-02 | 2024-06-06 | Tranquis Therapeutics, Inc. | 2-arylbenzimidazole compounds for the treatment of hemoglobinopathies |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3335052A (en) * | 1961-03-01 | 1967-08-08 | Merck & Co Inc | Anthelmintic composition and method of using same |
| US20050282780A1 (en) * | 2004-05-20 | 2005-12-22 | Richard Labaudiniere | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| WO2010142426A1 (en) * | 2009-06-11 | 2010-12-16 | Siena Biotech S.P.A. | Hedgehog pathway antagonists and therapeutic applications thereof |
| US20120245185A1 (en) * | 2009-11-06 | 2012-09-27 | Vanderbilt University | Aryl and heteroaryl sulfones as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US20150216168A1 (en) * | 2012-09-05 | 2015-08-06 | Bayer Cropscience Ag | Use of substituted 2-amidobenzimidazoles, 2-amidobenzoxazoles and 2-amidobenzothiazoles or salts thereof as active substances against abiotic plant stress |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1569337A (https=) * | 1968-06-18 | 1969-05-30 | ||
| US4038396A (en) * | 1975-02-24 | 1977-07-26 | Merck & Co., Inc. | Anti-inflammatory oxazole[4,5-b]pyridines |
| GB1584296A (en) | 1976-12-07 | 1981-02-11 | Kanebo Ltd | 2-substituted benzimidazole compounds |
| NZ234564A (en) * | 1986-11-21 | 1991-04-26 | Haessle Ab | 1-substituted benzimidazoles and pharmaceutical compositions |
| DE3830060A1 (de) | 1988-09-03 | 1990-03-15 | Boehringer Mannheim Gmbh | 2-phenylbenzimidazole - verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel |
| US5552426A (en) | 1994-04-29 | 1996-09-03 | Eli Lilly And Company | Methods for treating a physiological disorder associated with β-amyloid peptide |
| JPH09169729A (ja) * | 1995-12-19 | 1997-06-30 | Green Cross Corp:The | 非ペプチド型インターロイキン８拮抗剤 |
| JP4373497B2 (ja) * | 1996-06-19 | 2009-11-25 | ローン−プーラン・ロレ・リミテツド | 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用 |
| JP2000143635A (ja) * | 1998-06-10 | 2000-05-26 | Takeda Chem Ind Ltd | 血管新生阻害剤 |
| JP2000095767A (ja) * | 1998-09-28 | 2000-04-04 | Takeda Chem Ind Ltd | 性腺刺激ホルモン放出ホルモン拮抗剤 |
| IL142917A0 (en) * | 1998-11-03 | 2002-04-21 | Basf Ag | Substituted 2-phenylbenzimidazoles, the production thereof and their use |
| WO2002046168A1 (en) * | 2000-12-07 | 2002-06-13 | Astrazeneca Ab | Therapeutic benzimidazole compounds |
| DE10134775A1 (de) * | 2001-07-06 | 2003-01-30 | Schering Ag | 1-Alkyl-2.aryl-benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate |
| SE0301371D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | New Compounds |
| AU2005264998A1 (en) | 2004-06-17 | 2006-01-26 | Wyeth | The present invention relates to methods of making Gonadotropin Releasing Hormone ('GnRH') (also known as Leutinizing Hormone Releasing Hormone) receptor antagonists |
| WO2006122546A1 (de) * | 2005-05-18 | 2006-11-23 | Forschungsverbund Berlin E.V. | Nicht-peptidische inhibitoren der akap-pka-wechselwirkung |
| ES2344275T3 (es) | 2005-07-28 | 2010-08-23 | Intervet International Bv | Nuevos (tio) carbamatos de benzimidazol con actividad antiparasitaria y sintesis de ellos. |
| DK1910384T3 (da) | 2005-08-04 | 2012-12-17 | Sirtris Pharmaceuticals Inc | Imidazo [2,1-b] thiazol-derivater som sirtuinmodulerende forbindelser |
| ATE523497T1 (de) | 2006-11-15 | 2011-09-15 | High Point Pharmaceuticals Llc | Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen |
| GB0807103D0 (en) * | 2008-04-18 | 2008-05-21 | Univ Bradford The | Compounds |
| US9095596B2 (en) * | 2009-10-15 | 2015-08-04 | Southern Research Institute | Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such |
| GB201009656D0 (en) * | 2010-06-09 | 2010-07-21 | Univ St Andrews | Carboxylation catalysts |
| JP5083393B2 (ja) | 2010-09-16 | 2012-11-28 | カシオ計算機株式会社 | 画像表示装置及びプログラム |
| WO2012080729A2 (en) * | 2010-12-14 | 2012-06-21 | Electrophoretics Limited | CASEIN KINASE 1δ (CK1δ) INHIBITORS |
| WO2012118935A1 (en) * | 2011-03-03 | 2012-09-07 | Proteotech Inc | Compounds for the treatment of neurodegenerative diseases |
| JP6182593B2 (ja) | 2012-04-20 | 2017-08-16 | アドヴィーナス セラピューティクス リミテッド | 置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途 |
| KR101435496B1 (ko) * | 2012-10-22 | 2014-08-28 | 한국과학기술연구원 | 미토콘드리아 기능 조절제로서의 벤즈이미다졸 유도체 |
| GB201302927D0 (en) * | 2013-02-20 | 2013-04-03 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| CN103113307B (zh) * | 2013-02-27 | 2015-08-05 | 南京大学 | 苯并咪唑类化合物及其应用 |
| US10022357B2 (en) * | 2013-04-29 | 2018-07-17 | The General Hospital Corporation | Amyloid precursor protein MRNA blockers for treating Down syndrome and Alzheimer's disease |
| CA3000985C (en) | 2014-10-14 | 2023-01-31 | The Board Of Trustees Of The Leland Stanford Junior University | Method for treating neurodegenerative diseases |
| CN104873500A (zh) | 2015-04-29 | 2015-09-02 | 中国人民解放军第四军医大学 | 化合物zln005的用途 |
| CA2984971A1 (en) * | 2015-05-11 | 2016-11-17 | Kancera Ab | Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity |
| AU2016371598B2 (en) * | 2015-12-15 | 2021-05-13 | The Board Of Trustees Of The Leland Stanford Junior University | Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation |
| US10654814B2 (en) * | 2015-12-22 | 2020-05-19 | Kancera Ab | Bicyclic hydroxamic acids useful as inhibitors of mammalian histone deacetylase activity |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| KR20210068399A (ko) | 2018-08-06 | 2021-06-09 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 주니어 유니버시티 | 신경퇴행성 질병의 치료를 위한 피피에이알지씨1알파 활성제로서 2-아릴벤즈이미다졸 |
-
2019
- 2019-08-06 KR KR1020217006736A patent/KR20210068399A/ko not_active Ceased
- 2019-08-06 MX MX2021001456A patent/MX2021001456A/es unknown
- 2019-08-06 CN CN201980065941.4A patent/CN112805000A/zh active Pending
- 2019-08-06 AU AU2019319745A patent/AU2019319745B2/en active Active
- 2019-08-06 BR BR112021002165-5A patent/BR112021002165A2/pt not_active Application Discontinuation
- 2019-08-06 TW TW108127925A patent/TWI904076B/zh active
- 2019-08-06 IL IL307972A patent/IL307972A/en unknown
- 2019-08-06 IL IL280664A patent/IL280664B2/en unknown
- 2019-08-06 CA CA3108773A patent/CA3108773A1/en active Pending
- 2019-08-06 EP EP19845943.0A patent/EP3833344A4/en active Pending
- 2019-08-06 US US17/266,433 patent/US12195432B2/en active Active
- 2019-08-06 WO PCT/US2019/045229 patent/WO2020033359A1/en not_active Ceased
- 2019-08-06 IL IL298535A patent/IL298535B2/en unknown
- 2019-08-06 JP JP2021506624A patent/JP7422737B2/ja active Active
- 2019-08-06 SG SG11202101285YA patent/SG11202101285YA/en unknown
- 2019-08-06 CN CN202411199938.0A patent/CN119033775A/zh active Pending
-
2020
- 2020-05-29 US US16/888,040 patent/US10851066B2/en active Active
- 2020-10-13 US US17/068,985 patent/US11111217B2/en active Active
-
2021
- 2021-02-04 MX MX2023012694A patent/MX2023012694A/es unknown
-
2024
- 2024-01-16 JP JP2024004449A patent/JP2024056694A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3335052A (en) * | 1961-03-01 | 1967-08-08 | Merck & Co Inc | Anthelmintic composition and method of using same |
| US20050282780A1 (en) * | 2004-05-20 | 2005-12-22 | Richard Labaudiniere | Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| WO2010142426A1 (en) * | 2009-06-11 | 2010-12-16 | Siena Biotech S.P.A. | Hedgehog pathway antagonists and therapeutic applications thereof |
| US20120245185A1 (en) * | 2009-11-06 | 2012-09-27 | Vanderbilt University | Aryl and heteroaryl sulfones as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US20150216168A1 (en) * | 2012-09-05 | 2015-08-06 | Bayer Cropscience Ag | Use of substituted 2-amidobenzimidazoles, 2-amidobenzoxazoles and 2-amidobenzothiazoles or salts thereof as active substances against abiotic plant stress |
Non-Patent Citations (6)
| Title |
|---|
| ADV. SYNTH. CATAL., 2013, VOL. 355, PAGES 529-536. * |
| ADV. SYNTH. CATAL., 2018, vol. 360, pages 3220-3227. * |
| CAS Registry Number 1513993-57-1; STN Entry Date 8 January 2014 * |
| CHEMICAL SCIENCE, vol. 6, pages 6792-6798. * |
| J. PHYS. CHEM, 1982, vol. 86, pages 5223 - 5226. * |
| NEUROSCIENCE LETTERS, 2016, vol. 624, pages 1 - 7. * |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021002165A2 (pt) | 2021-05-04 |
| EP3833344A4 (en) | 2022-07-06 |
| US20210061769A1 (en) | 2021-03-04 |
| SG11202101285YA (en) | 2021-03-30 |
| CA3108773A1 (en) | 2020-02-13 |
| US20210300877A1 (en) | 2021-09-30 |
| IL298535B2 (en) | 2024-03-01 |
| US10851066B2 (en) | 2020-12-01 |
| IL307972A (en) | 2023-12-01 |
| TW202019410A (zh) | 2020-06-01 |
| MX2021001456A (es) | 2021-05-27 |
| US11111217B2 (en) | 2021-09-07 |
| EP3833344A1 (en) | 2021-06-16 |
| MX2023012694A (es) | 2023-11-21 |
| TWI904076B (zh) | 2025-11-11 |
| JP2024056694A (ja) | 2024-04-23 |
| IL280664A (en) | 2021-03-25 |
| US12195432B2 (en) | 2025-01-14 |
| IL298535A (en) | 2023-01-01 |
| CN112805000A (zh) | 2021-05-14 |
| KR20210068399A (ko) | 2021-06-09 |
| IL280664B2 (en) | 2023-04-01 |
| IL280664B (en) | 2022-12-01 |
| JP2021534099A (ja) | 2021-12-09 |
| CN119033775A (zh) | 2024-11-29 |
| IL298535B1 (en) | 2023-11-01 |
| WO2020033359A1 (en) | 2020-02-13 |
| AU2019319745A1 (en) | 2021-03-25 |
| US20200299244A1 (en) | 2020-09-24 |
| JP7422737B2 (ja) | 2024-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019319745B2 (en) | 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases | |
| ES2380395T3 (es) | Triazolopiridinas como inhibidores de fosfodiesterasa para el tratamiento de enfermedades dérmicas | |
| ES2459468T3 (es) | Arilpiridinas como inhibidores de aldosterona sintasa | |
| TWI448454B (zh) | Ｔｒｐｍ８拮抗劑及其治療用途 | |
| AU2007230911A1 (en) | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses | |
| AU2005286701A1 (en) | Compounds for inflammation and immune-related uses | |
| JP2016506367A (ja) | キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物 | |
| TW201925173A (zh) | 鹵代烯丙基胺類ssao/vap-1抑制劑及其用途 | |
| EP3986879B1 (en) | Fused 1,2-thiazoles and 1,2-thiazines which act as nlrp3 modulators | |
| WO2009085256A1 (en) | Anti-hiv compounds | |
| JP2019509272A (ja) | 脊髄性筋萎縮症の治療のための併用療法 | |
| JP2015528009A (ja) | ヒストン脱アセチル化酵素阻害剤ならびにその組成物およびその使用方法 | |
| JP2024529508A (ja) | ピロロ［２，３－ｂ］ピリジンＰＧＤＨ阻害剤、および製造方法ならびに使用方法 | |
| CN109843879B (zh) | 作为dyrk1抑制剂的苯并噻唑衍生物 | |
| TW202502756A (zh) | 作為ｉｌ１７的調節劑的新穎化合物 | |
| TW202229277A (zh) | 用於治療隱孢子蟲病之化合物及組成物 | |
| EP4522623A1 (en) | Compositions useful for modulating splicing | |
| CN110467611B (zh) | 亚氨基噻二嗪二氧化物衍生物及其用途 | |
| JP2024520758A (ja) | Ｔｔｂｋ１の阻害剤 | |
| JP2025518047A (ja) | ＴＲＰＭ３媒介性障害を治療するためのピラゾロ［１，５－ａ］ピリジン誘導体 | |
| OA17463A (en) | Inhibitors of histone demethylases. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TH | Corrigenda |
Free format text: IN VOL 59 , NO 4 , PAGE(S) 547 UNDER THE HEADING APPLICATIONS ACCEPTED - NAME INDEX DELETE ALL REFERENCE TO 2019319745. |
|
| FGA | Letters patent sealed or granted (standard patent) |